Investor Backing & Capital Strength:
A March 2026 $1.5B Series G plus $500M in preferred equity at a $12.7B valuation underscores deep capital support and balance‑sheet capacity. Prior financing in 2025 and corroborated reports indicate consistent fundraising momentum.
Strong Revenue Growth:
Company leadership outlined a 2026 revenue outlook above $540M, building on 2025 results. Production‑path awards and ongoing contract activity indicate movement from R&D into higher‑scale revenue.
Market Expansion:
Activity spans U.S. programs and allied markets, including Japan, Romania, Greece, Canada, the Netherlands, Ukraine, and a February 2026 Taiwan agreement. Hiring and new offices in hubs like Taipei signal international scaling.
